

GALDERMA

EST. 1981

Notice Regarding Offer of Refunds to 340B Covered Entities

Galderma has recalculated 340B Ceiling Prices for the NDC listed below for the time period April 1, 2025 (2Q2025) through December 31, 2025 (4Q2025). As a result of the recalculated 340B Ceiling Prices, Galderma has determined that, pursuant to 42 U.S.C. § 256b(d)(1)(B)(ii) and 42 C.F.R. § 10.11(b)(4), a refund may be owed to 340B Covered Entities that purchased the product below during the period above.

The table below identifies the NDC that is subject to a refund. The recalculated Ceiling Prices are the result of revised pricing data that was submitted to the Centers for Medicare & Medicaid Services.

NDC	Description	Time Period
00299-6220-15	Nemluvio, 30mg/100mg, Injection	04/01/2025 – 06/30/2025 (Q2 2025)
00299-6220-15	Nemluvio, 30mg/100mg, Injection	07/01/2025 – 09/30/2025 (Q3 2025)
00299-6220-15	Nemluvio, 30mg/100mg, Injection	10/01/2025 – 12/31/2025 (Q4 2025)

For Covered Entities that Galderma has determined are owed a refund equal to or in excess of \$100, Galderma will work with Apexus to issue refunds directly to the 340B Covered Entity of record.

Galderma has requested the Health Resources and Services Administration (HRSA) to post this Notice on HRSA's public website to ensure transparency to all 340B Covered Entities regarding the Ceiling Price recalculations for the NDC identified above and to provide an opportunity for affected Covered Entities that may be owed less than \$100 to request a refund. Please direct any questions and/or requests for additional information to Galderma at the following email address: 340BRefunds@galderma.com.